Edwards Life Sciences recently announced its second-quarter results, with revenue of $1.74 billion, a 13.6% year-over-year increase, representing a significant growth.However, it's worth noting that net profit performance contrasts sharply with revenue growth. Net profit for the period was $241.9 million, a 27.4% year-over-year decline. Nevertheless, looking at each business segment, Edwards' core business remains solid.

As Edwards' core business, transcatheter aortic valve replacement (TAVR) sales reached $1.3 billion in the second quarter, up 11.3% year-over-year. This business accounts for approximately 75% of the company's total revenue and remains its absolute pillar.

Edwards attributed the growth of TAVR to continued clinical momentum and evidence-based support for active disease management of aortic stenosis. The company specifically highlighted the differentiated advantages of its Sapien TAVR platform, namely the 7-year follow-up data from the PARTNER 3 trial presented at the recent New York Heart Valve Conference, and the latest findings from the EARLY TAVR trial.

The transcatheter mitral and tricuspid valve therapy (TMTT) business, as the second growth curve, is accelerating its realization, with a strong performance in Q2, reaching $195.9 million in sales, a year-on-year increase of 47.3%. Edwards Life Sciences pointed out that the Evoque and Pascal systems are the main growth drivers.

In addition, Edwards’ Ecliptis left atrial appendage occlusion system has received FDA 510(k) clearance. This approval marks Edwards’ official entry into the left atrial appendage occlusion device market, where it will directly compete with AtriCure’s AtriClip and Medtronic’s Penditure.

Based on its second-quarter performance, Edwards raised the lower end of its full-year 2026 constant-currency sales growth guidance from 9%-11% to 10%-11%. TAVR growth guidance was increased by 1 percentage point to 8%-9%. The company reiterated its full-year adjusted earnings per share guidance range of $2.95 to $3.05.

In the earnings report, Edwards CEO Bernard Zovighian stated, "Our results increasingly reflect the strength of our comprehensive product portfolio and agile execution, with growth supported by a range of therapies including TAVR, mitral valve, tricuspid valve, and surgical, all making significant contributions across all regions. Today, the company's business landscape has evolved into multiple strategic platforms spanning multiple regions, which will support sustained growth and give us confidence in achieving our long-term average total sales growth target of approximately 10%."

Overall, this financial report presents a clear signal: Edwards is transitioning from a growth model driven solely by TAVR to a diversified structure with TAVR + TMTT dual engines, coupled with new surgical products. While the 47% growth rate of the TMTT business is impressive, its $196 million size is still orders of magnitude smaller than TAVR's $1.3 billion, making it unlikely to shake TAVR's dominant position in the short term. However, the discrepancy between the 27% decline in net profit and the 14% increase in revenue also warrants attention.

https://news.yaozh.com/archive/48777.html